Strong evidence shows that DCLK1 is a key regulator of the EMT program in gastric cancer, colorectal cancer, pancreatic cancer, breast cancer, renal cancer, and other tumors, and silencing DCLK1 expression can inhibit the EMT process in tumor cells by down-regulating Snail and Vimentin and upregulating E-cadherin [40,41,42]. This evidence concerns the gene VIM and breast carcinoma.